MannKind Corporation

MannKind Corporation

MNKD·NASDAQ

$3.36

-2.0%
HealthcareBiotechnology

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

At a Glance

Live Snapshot
Market Cap$1.04B
EPS0.0200
P/E Ratio168.00
Earnings Date08/05/2026

mnkd

Revenue

Last Annual Value

348.97M

3-Year CAGR

52%

5-Year CAGR

40%

10-Year CAGR

%

MannKind Corporation

MannKind Corporation Competitors Analysis of Revenue

MNKD · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
348.97M
20.6%35.8%7.2% 
10.00M
7.4%22.4%N/A
BHVN logo
Biohaven Ltd.
NYSE:BHVN
0.00
N/AN/AN/A
1.50M
-39.8%-20.3%-14.0%
868.45M
14.3%23.2%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
62.90M
N/AN/AN/A
MannKind Corporation

MannKind Corporation Fair Value Envelope

MNKD · NASDAQ

Our analysis suggests that MNKD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.36, this represents a potential HIDDEN relative to our calculated worth for MannKind Corporation.

Intrinsic Value
Current Price: $3.36